{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-atmp-trial-design-and-submissions-advanced-therapies”
},
“headline”: “SOP for ATMP Trial Design and Submissions (Advanced Therapies)”,
“description”: “This SOP provides standardized guidance for designing clinical trials and preparing regulatory submissions for Advanced Therapy Medicinal Products (ATMPs). It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements, covering protocol design, dossier preparation, ethics submissions, and global trial oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 21/12/2025
Standard Operating Procedure for ATMP Trial Design and Submissions (Advanced Therapies)
| SOP No. | CR/OPS/110/2025 |
| Supersedes | NA |
| Page No. | 1 of 50 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to establish standardized procedures for the design
Scope
This SOP applies to sponsors, investigators, CROs, regulatory affairs specialists, and QA teams involved in ATMP clinical trials. It covers trial design, protocol development, ethics and regulatory submissions, dossier preparation, global submission requirements, and oversight of ATMP-specific risks and long-term follow-up.
Responsibilities
- Sponsor: Oversees ATMP trial design, dossier preparation, and regulatory submissions.
- Regulatory Affairs: Prepares and manages submissions to FDA, EMA, CDSCO, and other authorities.
- Investigator: Ensures proper design and execution of ATMP trials at site level.
- CRO: Supports monitoring and documentation for ATMP compliance.
- QA: Verifies adherence to ATMP-specific GCP and GMP requirements.
Accountability
The Sponsor’s Head of Regulatory Affairs is accountable for ensuring ATMP trial design and submissions meet global regulatory requirements. Investigators are accountable for site-level trial execution.
Procedure
1. Trial Design
1.1 Define study objectives, endpoints, and patient population.
1.2 Conduct risk-benefit assessment specific to ATMPs.
1.3 Design inclusion/exclusion criteria addressing ATMP risks.
1.4 Document in ATMP Trial Design Log (Annexure-1).
2. Protocol Development
2.1 Develop protocol including manufacturing, administration, and follow-up requirements.
2.2 Include long-term follow-up design for gene and cell therapies.
2.3 Record in Protocol Development Log (Annexure-2).
3. Ethics and Regulatory Submissions
3.1 Submit trial documents to EC/IRB for review and approval.
3.2 Submit to regulatory authorities (FDA IND, EMA CTA, CDSCO CTN/CTA).
3.3 Maintain Regulatory Submission Log (Annexure-3).
4. Dossier Preparation
4.1 Prepare dossier with preclinical, manufacturing, and clinical data.
4.2 Ensure compliance with region-specific ATMP requirements.
4.3 Record in Dossier Preparation Log (Annexure-4).
5. Risk Management
5.1 Develop Risk Management Plan addressing ATMP-specific risks.
5.2 Maintain in Risk Management Log (Annexure-5).
6. Global Oversight
6.1 Coordinate submissions across multiple regions.
6.2 Track approvals and responses in Global Oversight Log (Annexure-6).
7. Archiving
7.1 Archive trial design, submission, and approval records in TMF.
7.2 Retain records as per regulatory timelines.
Abbreviations
- SOP: Standard Operating Procedure
- ATMP: Advanced Therapy Medicinal Products
- QA: Quality Assurance
- CRO: Contract Research Organization
- TMF: Trial Master File
- FDA: Food and Drug Administration
- EMA: European Medicines Agency
- CDSCO: Central Drugs Standard Control Organization
- IRB/EC: Institutional Review Board/Ethics Committee
- CTA: Clinical Trial Application
- CTN: Clinical Trial Notification
- IND: Investigational New Drug Application
Documents
- ATMP Trial Design Log (Annexure-1)
- Protocol Development Log (Annexure-2)
- Regulatory Submission Log (Annexure-3)
- Dossier Preparation Log (Annexure-4)
- Risk Management Log (Annexure-5)
- Global Oversight Log (Annexure-6)
References
- FDA – Cellular & Gene Therapy Guidance
- EMA – ATMP Guidelines
- CDSCO – ATMP Clinical Trial Rules
- ICH GCP – ATMP Trial Guidance
- WHO – Advanced Therapy Medicinal Products Recommendations
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, Regulatory Specialist |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Head Clinical Operations |
Annexures
Annexure-1: ATMP Trial Design Log
| Date | Study Title | Objective | Designed By | Status |
|---|---|---|---|---|
| 01/09/2025 | CAR-T Cell Therapy Study | Assess efficacy in oncology | Regulatory Team | Completed |
Annexure-2: Protocol Development Log
| Date | Protocol ID | Activity | Prepared By | Status |
|---|---|---|---|---|
| 05/09/2025 | ATMP-2025-01 | Protocol Drafted | Medical Writer | Completed |
Annexure-3: Regulatory Submission Log
| Date | Agency | Submission Type | Submitted By | Status |
|---|---|---|---|---|
| 10/09/2025 | FDA | IND Submission | Regulatory Affairs | Submitted |
Annexure-4: Dossier Preparation Log
| Date | Dossier ID | Activity | Prepared By | Status |
|---|---|---|---|---|
| 12/09/2025 | ATMP-D-2025-01 | Dossier Compiled | Regulatory Team | Completed |
Annexure-5: Risk Management Log
| Date | Risk | Impact | Mitigation | Reviewed By |
|---|---|---|---|---|
| 15/09/2025 | Long-term immunogenicity | High | Extended follow-up | QA |
Annexure-6: Global Oversight Log
| Date | Region | Submission | Status | Responsible |
|---|---|---|---|---|
| 20/09/2025 | EU | CTA | Submitted | Regulatory Affairs |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head Clinical Operations |
For more SOPs visit: Pharma SOP